Chapter 3 – Comprehensive review 103 35. Brunia CHM, van Boxtel GJM. Wait and see. International Journal of Psychophysiology. 2001;43(1):59-75. doi:10.1016/S0167-8760(01)00179-9 36. Chiu P, Ambady N, Deldin P. Contingent Negative Variation to Emotional In- and Out-Group Stimuli Differentiates High- and Low-Prejudiced Individuals. Journal of Cognitive Neuroscience. 2004;16(10):1830-1839. doi:10.1162/0898929042947946 37. Nagai Y, Critchley HD, Featherstone E, Fenwick PBC, Trimble MR, Dolan RJ. Brain activity relating to the contingent negative variation: an fMRI investigation. NeuroImage. 2004;21(4):1232-1241. doi:10.1016/J.NEUROIMAGE.2003.10.036 38. Osterweis M, Kleinman A, Mechanic D. The Anatomy and Physiology of Pain. In: Institute of Medicine (US) Committee on Pain, Disability and CIB, ed. Pain and Disability: Clinical, Behavioral, and Public Policy Perspectives. National Academies Press (US); 1987. 39. Colloca L, Benedetti F. Nocebo hyperalgesia: how anxiety is turned into pain. Current Opinion in Anaesthesiology. 2007;20(5):435-439. doi:10.1097/ACO.0b013e3282b972fb 40. Colagiuri B, Quinn VF. Autonomic Arousal as a Mechanism of the Persistence of Nocebo Hyperalgesia. The journal of pain : official journal of the American Pain Society. 2018;19(5):476-486. doi:10.1016/j.jpain.2017.12.006 41. Egorova N, Yu R, Kaur N, et al. Neuromodulation of conditioned placebo/nocebo in heat pain: Anodal vs cathodal transcranial direct current stimulation to the right dorsolateral prefrontal cortex. Pain. 2015;156(7):1342-1347. doi:10.1097/j.pain.0000000000000163 42. Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell. 2009;139(2):267-284. doi:10.1016/j.cell.2009.09.028 43. Thomaidou MA, Veldhuijzen DS, Meulders A, Evers AWM. An experimental investigation into the mediating role of pain-related fear in boosting nocebo hyperalgesia. PAIN®. 2021;162(1):287-299. doi:10.1097/j.pain.0000000000002017 44. Bunney BS, Chiodo LA, Freeman AS. Further studies on the specificity of proglumide as a selective cholecystokinin antagonist in the central nervous system. Annals of the New York Academy of Sciences. 1985;448:345-351. 45. Riss J, Cloyd J, Gates J, Collins S. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurologica Scandinavica. 2008;118(2):69-86. doi:10.1111/j.1600-0404.2008.01004.x 46. Benedetti F, Amanzio M, Casadio C, Oliaro A, Maggi G. Blockade of nocebo hyperalgesia by the cholecystokinin antagonist proglumide. Pain. 1997;71(2):135-140. doi:10.1016/S0304 47. Richalet JP, Hornych A, Rathat C, Aumont J, Larmignat P, Rémy P. Plasma prostaglandins, leukotrienes and thromboxane in acute high altitude hypoxia. Respiration Physiology. 1991;85(2):205-215. doi:10.1016/0034-5687(91)90062-N 48. Burtscher M, Likar R, Nachbauer W, Philadelphy M. Aspirin for prophylaxis against headache at high altitudes: randomised, double blind, placebo controlled trial. BMJ (Clinical research ed). 1998;316(7137):1057-1058. doi:10.1136/BMJ.316.7137.1057 49. Hill AT, Fitzgerald PB, Hoy KE. Effects of Anodal Transcranial Direct Current Stimulation on Working Memory: A Systematic Review and Meta-Analysis of Findings From Healthy and Neuropsychiatric Populations. Brain Stimulation. 2016;9(2):197-208. doi:10.1016/J.BRS.2015.10.006 50. Kuo MF, Nitsche MA. Exploring prefrontal cortex functions in healthy humans by transcranial electrical stimulation. Neurosci Bull. 2015;31(2):198-206. doi:10.1007/s12264-014-1501-9
RkJQdWJsaXNoZXIy MTk4NDMw